Your Messages Inbox
Your Article Summary
See Latest ArticlesDiscontinuation due to adverse events in randomized trials of orlistat, sibutramine and rimonabant: a meta-analysis
Obesity Reviews, 08/27/09
Johansson K et al. – Available weight loss drugs differ markedly regarding risk of discontinuation due to adverse events, as well as in underlying causes of these events. Given the large number of patients eligible for treatment, the low NNH for rimonabant is a concern.
Related Articles
Efficacy and Safety of Ezetimibe Plus Orlistat or Rimonabant in Statin-Intolerant Nondiabetic Overweight/Obese Patients With Dyslipidemia
Journal of Cardiovascular Pharmacology and Therapeutics, 11/12/09
Relevance Score: 66%
Efficacy and safety of anti-obesity drugs in children and adolescents: systematic review and meta-analysis
Obesity Reviews, 11/18/09
Relevance Score: 65%
The value of drugs for obesity in the management of cardiovascular risk factors
Sang Thrombose Vaisseaux, 11/04/09
Relevance Score: 64%
Early Response to Sibutramine in Patients Not Meeting Current Label Criteria: Preliminary Analysis of SCOUT Lead-in Period
Obesity, 10/14/09
Relevance Score: 44%
FDA Issues Early Communication About Ongoing Safety Review of Weight Loss Drug Orlistat
Gastroenterology, 10/27/09
Relevance Score: 43%
Today in Drug Trials...keeping you current
Receive free subspecialty "5-minute updates" via email
Sanofi Pasteur expands study of vaccine against Clostridium difficile into the U.S.
Sanofi-aventis, 12/16/09
A Clinical Review of Echinocandins in Pediatric Patients
Annals of Pharmacotherapy, 12/16/09
Second Pivotal Phase III Study of Gileads Darusentan for Resistant Hypertension Misses Primary Endpoints
Gilead, 12/15/09
Article Search
Sponsor